Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Guided Therapeutcs Inc (OP:GTHP)

0.3900 UNCHANGED
Streaming Delayed Price Updated: 2:39 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.3900
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.3900
Today's Range 0.3900 - 0.3900
52wk Range 0.0644 - 0.5400
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Analysis of Guided Therapeutics' FDA Study Data Reveals Compelling Clinical Need for LuViva
From Guided Therapeutics, Inc.
Via Business Wire
News headline image
Guided Therapeutics Receives $88,000 Payment as Third Installment of $700,000 Purchase Order with Chinese Distributor
From Guided Therapeutics, Inc.
Via Business Wire

Performance

YTD
-27.8%
-27.8%
1 Month
+7.0%
+7.0%
3 Month
+57.0%
+57.0%
6 Month
+100.0%
+100.0%
1 Year
+200.0%
+200.0%

More News

Read More
News headline image
Guided Therapeutics Inks Initial $200,000 Deal with New Distribution Partner Yuanshuo Medical Instruments Corporation
From Guided Therapeutics, Inc.
Via Business Wire
News headline image
Guided Therapeutics Receives $70,000 -- Its Second of Nine Payments Totaling $700,000 -- from New Chinese Distribution Partner that Provides Products for 2 Million Annual Cervical Cancer Screenings
From Guided Therapeutics, Inc.
Via Business Wire
News headline image
Guided Therapeutics Provides Update on Completion of US FDA Clinical Trial
From Guided Therapeutics, Inc.
Via Business Wire
News headline image
Guided Therapeutics Makes Initial Shipment to New Chinese Distribution Partner Hangzhou Dongye Medical Technology, Ltd.
From Guided Therapeutics, Inc.
Via Business Wire
News headline image
Guided Therapeutics Receives $700,000 Purchase Order and Initial Payment from New Chinese Distributor
From Guided Therapeutics, Inc.
Via Business Wire
News headline image
Guided Therapeutics Receives $100,000 from SMI’s Investment Partners to Continue Commercialization Process of LuViva in China
From Guided Therapeutics, Inc.
Via Business Wire
News headline image
Guided Therapeutics Receives Order and Full Payment From Indonesia for 4 LuViva Systems and 1,200 Disposables
From Guided Therapeutics, Inc.
Via Business Wire
News headline image
Guided Therapeutics Announces Filing of Application for NMPA Approval to Market and Sell LuViva in China
From Guided Therapeutics, Inc.
Via Business Wire
News headline image
Guided Therapeutics’ Announces Data from Chinese NMPA Clinical Study Signed Off by All Four Clinical Sites With Better Than Expected Results
From Guided Therapeutics, Inc.
Via Business Wire
News headline image
Leading Cervical Cancer Doctors Support Approval of LuViva in China Based on Preliminary Review of Clinical Trial Results
From Guided Therapeutics, Inc.
Via Business Wire
News headline image
Guided Therapeutics Announces Completion of Clinical Study for Chinese Regulatory Approval
From Guided Therapeutics, Inc.
Via Business Wire
News headline image
Guided Therapeutics Provides Update on Start of Clinical Trial for US FDA Approval
From Guided Therapeutics, Inc.
Via Business Wire
News headline image
Guided Therapeutics Announces New Agreement and Purchase Orders from Shandong Yaohua Medical Instrument Corporation
From Guided Therapeutics, Inc.
Via Business Wire
News headline image
Guided Therapeutics Signs Agreement to Begin Clinical Trial for US FDA Approval
From Guided Therapeutics, Inc.
Via Business Wire
News headline image
Guided Therapeutics Provides Update of Significant Progress in Chinese Clinical Study for Marketing Approval of the LuViva Advanced Cervical Scan
From Guided Therapeutics, Inc.
Via Business Wire
News headline image
Guided Therapeutics Closes $3.3 Million Bridge Financing
From Guided Therapeutics, Inc.
Via Business Wire
News headline image
Guided Therapeutics Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva® Advanced Cervical Scan
From Guided Therapeutics, Inc.
Via Business Wire
News headline image
Guided Therapeutics Announces Testing Completion of First 150 Patients in Chinese Clinical Study and Receives Milestone Payment of $177,740
From Guided Therapeutics, Inc.
Via Business Wire
News headline image
Guided Therapeutics Announces Start of Chinese Clinical Trial for Approval to Market and Sell LuViva in China
From Guided Therapeutics, Inc.
Via Business Wire
News headline image
Guided Therapeutics Ships LuViva Devices to China for Start of Clinical Trial; Receives Additional $100,000 Payment
From Guided Therapeutics, Inc.
Via Business Wire
News headline image
Guided Therapeutics Receives Notification of Successful Clinical Trial Regulatory Review and $133,000 Payment from China
From Guided Therapeutics, Inc.
Via Business Wire
News headline image
New European Published Study Shows LuViva Detects 20% More Precancerous and Cancerous Cervical Disease than HPV Test
From Guided Therapeutics, Inc.
Via Business Wire
News headline image
Guided Therapeutics Receives News from Chinese State Food and Drug Administration that LuViva Meets Product Technical Requirements
From Guided Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Guided Therapeutcs Inc publicly traded?
Yes, Guided Therapeutcs Inc is publicly traded.
What exchange does Guided Therapeutcs Inc trade on?
Guided Therapeutcs Inc trades on the OTC Traded
What is the ticker symbol for Guided Therapeutcs Inc?
The ticker symbol for Guided Therapeutcs Inc is GTHP on the OTC Traded
What is the current price of Guided Therapeutcs Inc?
The current price of Guided Therapeutcs Inc is 0.3900
When was Guided Therapeutcs Inc last traded?
The last trade of Guided Therapeutcs Inc was at 02/10/26 02:39 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.